1800 244 735

Helpline (02) 9874 9777

The structure of the protein that causes Huntington's disease, revealed

The cause of Huntington’s disease has been known since 1993, but the physical structure of the healthy huntingtin protein proved difficult to discover until now. German scientists have now revealed the shape of the huntingtin protein for the first time. Although the structure of the mutant form of the protein was not investigated, this study provides an excellent platform to build upon and will boost drug development efforts.

Know your enemy

One of the biggest issues in HD research to date is that although we know what causes the disease – a harmful protein called mutant huntingtin. We even know some ways in which the mutant protein wreaks havoc within the human brain. But until now we’ve had no idea what the protein actually looks like. That makes trying to prevent it causing damage very difficult! Imagine you’re a farmer whose crops are being damaged by an animal every night. If you had a photo of the animal that was causing the damage, it would be easier to figure out how to prevent it. A drunk elephant would require a different strategy from a swarm of locusts. It’s the same when we’re fighting brain diseases: knowing what a protein looks like is a huge help when it comes to understanding how it operates and how to make drugs to change its behaviour.

Cool science – literally

The technique used in this particular study is the crème de la crème of microscopy, so much so that it was awarded the Nobel Prize for Chemistry last year. It’s called cryo-electron microscopy, otherwise known as cryo-EM. It involves shooting a beam of electrons at a sample that’s been frozen using a super-cold liquid. When we say cool we don’t mean like a beer or a smoothie – this technique involves cooling proteins to several hundred degrees below freezing.

When the electrons hit the sample, it causes them to scatter slightly before striking an electron detector, which builds up an image like the light detector in a digital camera. But one image isn’t enough – hundreds of ‘photos’ have to be taken from different angles, then combined by computer to reveal the 3D shape of the protein.

The images generated by cryo-EM are so precise that the authors of this study – a team led by Stefan Kochanek at the University of Ulm – were able to document the structure of huntingtin down to a billionth of a centimetre! The study found that the protein was essentially composed of two parts, connected by a bridge region. This is a very important finding as it suggests that the function of huntingtin could be to act as a kind of protein hub. In other words, it’s a mothership that lots of different protein spaceships dock into.

What’s the big deal?

You might be thinking to yourself, why has it taken such a long time to figure this out? Basically, it’s due to how complicated and bendy the huntingtin protein is. In order to build up a 3D image of the protein, it has to be photographed from multiple different angles, but for the pieces of the puzzle to slot together perfectly, the protein has to remain in the same position for this entire process. Unfortunately for us, this doesn’t happen with the huntingtin protein alone. To get around this, the researchers of this study used another protein called ‘huntingtin-associated protein 40’ or HAP40, which was able to bind to both segments of HTT as well as the bridge region and essentially fix it in one position, to stop it moving around. This stabilised the protein for long enough that the ‘photoshoot’ could take place.

What about the mutant protein?

The structure that was just announced was of the normal, healthy huntingtin protein that scientists call ‘wild-type’. But what about the structure of mutant huntingtin? Surely we need to know the what that protein looks like, to actually help in HD?

On the one hand yes, there is still an urgent need to identify the structure of the harmful version of huntingtin, and that would be super-helpful for designing therapies to combat the mutant protein’s harmful effects. However, that poses a whole host of other potential challenges to researchers.

Unfortunately, the presence of the mutation changes the the way the protein interacts with other proteins. That’s probably one of the things that makes it harmful. Remember that the success of the photoshoot depended on huntingtin sticking to another protein, HAP40. But the presence of the mutation may mean that huntingtin and HAP40 no longer stick together so well, meaning the cryo-EM photoshoot doesn’t work so well. The authors hinted at this problem in their article.

How can this help?

The structure of the mutant protein will hopefully come in time, now that the healthy one has shown its face. But just knowing the structure of the healthy huntingtin protein is already a big deal. Despite decades of research, we still don’t understand all the jobs huntingtin carries out in our cells, not just in the brain but the whole body. But since the structure of a protein basically dictates how it interacts with other molecules, we can now use these results to work out what different functions huntingtin might have, and how it achieves them. Essentially, this finding is a lightbulb that means we’re no longer shooting in the dark to understand and reveal huntingtin function.

Finally, this finding will be a big boost for efforts to invent new drugs to fight Huntington’s disease, especially if it does lead to uncovering what the mutant protein looks like. It could enable the design of targeted drugs that make the huntingtin protein less toxic whilst protecting the helpful functions of the healthy protein. Hopefully, this discovery will kickstart a new era for targeted drug development in Huntington’s disease, focused on the known structure of the huntingtin protein.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Published date: 15 July, 2020

Dopamine is an important chemical messenger in the brain that becomes imbalanced in Huntington’s disease. Researchers recently described a creative way to restore the balance and treat symptoms in HD mice, using an antihistamine drug that acts on hybrid dopamine receptors. It’s an innovative approach to HD therapeutics, but don’t start reaching for allergy meds ... Read more HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.